Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,002.95 +2.16 (+0.22%) Streaming Delayed Price Updated: 4:00 PM EDT, Jun 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond May 02, 2024 It pays to develop novel medicines for life-threatening illnesses. Via The Motley Fool Regeneron Earnings Miss; Biotech Giant's Stock Falls May 02, 2024 The biotech giant's earnings and sales both missed Q1 estimates. Via Investor's Business Daily 10 Health Care Stocks With Whale Alerts In Today's Session April 30, 2024 Via Benzinga Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends April 30, 2024 Via Benzinga AbbVie's Dermatitis Drug Shown 'Superior' To Sanofi/Regeneron's Dupixent In Head-To-Head Study April 25, 2024 AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficacy and rapid skin clearance than Dupixent. Via Benzinga Market Analysis: Regeneron Pharmaceuticals And Competitors In Biotechnology Industry April 18, 2024 Via Benzinga If You Invested $100 In This Stock 20 Years Ago, You Would Have $6,700 Today April 17, 2024 Via Benzinga Breaking Down Regeneron Pharmaceuticals: 13 Analysts Share Their Views April 12, 2024 Via Benzinga Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking April 11, 2024 Via Benzinga 2 Small-Cap Growth Stocks With Room To Run April 24, 2024 These two small-cap growth stocks could be ready to run. Via The Motley Fool Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick April 17, 2024 Amgen's Tezspire shows promising COPD trial results and potential market expansion beyond asthma. Comparison with Dupixent reveals significant benefits for eosinophil counts ≥150 cells/μL and ≥300... Via Benzinga Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review April 12, 2024 The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears. Via Investor's Business Daily Topics Economy Exposures Interest Rates Eye Drug Eylea Price Manipulation: Regeneron Faces US Justice Department Allegations Over Medicare Pricing Of Its Best-Selling Eye Drug April 11, 2024 The U.S. Justice Department accuses Regeneron Pharmaceuticals of Medicare fraud related to its macular degeneration drug, Eylea. Allegations include manipulating drug prices, resulting in inflated... Via Benzinga Topics Fraud Exposures Legal Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends March 28, 2024 Via Benzinga Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals March 26, 2024 Via Benzinga Regeneron Pharmaceuticals Unusual Options Activity For March 20 March 20, 2024 Via Benzinga Are Regeneron's Legal Troubles — And Six-Week Slide — A Buying Opportunity? April 11, 2024 Regeneron has fallen more than 6% over the past six weeks, and dropped again Thursday, as the DOJ focuses on its Eylea franchise. Via Investor's Business Daily Should You Sell This Stock Following a Regulatory Roadblock? April 05, 2024 It's not the first such obstacle this high-performing drugmaker has faced. Via The Motley Fool 5 Healthcare Stocks to Buy for 2024 April 02, 2024 Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up. Via InvestorPlace Topics Artificial Intelligence Exposures Artificial Intelligence Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today April 01, 2024 Via Benzinga Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback March 28, 2024 The FDA has delayed making a decision on Eli Lilly's donanemab, pending an advisory committee meeting. Via Investor's Business Daily Exposures Product Safety Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals March 15, 2024 Via Benzinga Stock-Split Watch: Are These 2 Top Growth Stocks Next? March 28, 2024 Shares of Eli Lilly and Regeneron are both well into the range where splits would make sense. Via The Motley Fool 3 Biotech Stocks to Buy for the Next Bull Run: March 2024 March 26, 2024 These biotech stocks to buy are well positioned for growth, and will generate solid returns for investors in the next bull run. Via InvestorPlace FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns March 25, 2024 The FDA issues complete response letters to Regeneron Pharmaceuticals Inc's BLA for odronextamab in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma, requesting more trial data... Via Benzinga Exposures Product Safety Hot Stocks: The 3 Best Opportunities for Investing in Weight Loss Drugs March 22, 2024 The market for weight loss drug stocks is massive, and these three companies could be the biggest beneficiaries of this trend. Via InvestorPlace The 3 Most Undervalued Biotech Stocks to Buy in March 2024 March 13, 2024 These 3 undervalued biotech stocks have been left behind so far but things could begin to turn around as we head into March. Via InvestorPlace NVIDIA To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday March 13, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Missed Out on Eli Lilly? 3 Healthcare Stocks With Big Catalysts on the Horizon. March 09, 2024 Good news could be in store for all three of these drugmakers. Via The Motley Fool Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years March 08, 2024 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 31 32 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.